Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Non-Current Assets data on record, last reported at $44.6 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 16.12% year-over-year to $44.6 million; the TTM value through Sep 2025 reached $190.7 million, down 19.65%, while the annual FY2024 figure was $49.9 million, 29.65% down from the prior year.
  • Non-Current Assets reached $44.6 million in Q3 2025 per SGMO's latest filing, down from $47.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $325.0 million in Q3 2021 and bottomed at $44.6 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $167.7 million, with a median of $165.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: soared 30.68% in 2021, then tumbled 72.92% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $323.2 million in 2021, then decreased by 18.87% to $262.2 million in 2022, then crashed by 72.92% to $71.0 million in 2023, then fell by 29.65% to $49.9 million in 2024, then decreased by 10.77% to $44.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $44.6 million in Q3 2025, $47.7 million in Q2 2025, and $48.6 million in Q1 2025.